5 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie

In this article, we will discuss 5 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie. If you want to read our detailed analysis of Lee Ainslie’s history, investment strategy, hedge fund performance, and some of the top pharmaceutical stocks in his 13F portfolio, go directly to the 10 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie. 

At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, lithium mining is one of the fastest growing industries right now, so we are checking out stock pitches like this emerging lithium stock. We go through lists like the 10 best hydrogen fuel cell stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage. Keeping this in mind, let’s take a look at billionaire Ainslie’s top 5 pharma stock picks:

5. Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA)

Maverick Capital’s Stake Value: $48,817,000
Percent of Maverick Capital’s 13F Portfolio: 0.45%
Number of Hedge Fund Holders: 27

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) is an American biopharmaceutical company that focuses on the discovery and development of medicines used to treat patients suffering from rare diseases.

In Q2, Maverick Capital holds over 1.3 million shares in Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), worth $48.8 million. The hedge fund sold over 44,700 shares in the company in the second quarter, reducing its position by 4%. The company currently accounts for 0.45% of the fund’s 13F portfolio. In Q2 2021, Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) posted revenue of $41.3 million, presenting a 2.2% year-over-year growth. Recently, B. Riley rated the stock as a ‘Buy’ with a $35 price target. In the past year, Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) has soared by 9.5%.

Of the 873 hedge funds tracked by Insider Monkey, 27 funds have positions in Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), worth $377.6 million.